Evidence map›Paper›PMID 29062331›Full record

Observational studyAfrican health sciences2017

Osteopontin as a marker for response to pegylated interferon Alpha-2b treatment in Chronic HCV Saudi patients.

Yousri Mostafa Hussein, Ayman Alhazmi, Saad Alzahrani, Ahmad El-Askary, Abdulrahman Alghamdy, Eman Bayomy, Assmaa Selim, Mohammed Alghamdy

Open access · diamondAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in African health sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Yousri Mostafa HusseinMedical Laboratories Department, Faculty of Applied Medical Sciences, Taif University, Saudi Arabia.
Ayman AlhazmiMedical Laboratories Department, Faculty of Applied Medical Sciences, Taif University, Saudi Arabia.
Saad AlzahraniCommunity Medicine Department, Faculty of Medicine, Taif University, Saudi Arabia.
Ahmad El-AskaryMedical Laboratories Department, Faculty of Applied Medical Sciences, Taif University, Saudi Arabia.
Abdulrahman AlghamdyCommunity medicine, Faculty of Applied Medical Sciences, Taif University, Saudi Arabia.
Eman BayomyMedical Biochemistry Department, Damietta Faculty of Medicine, Al-Azhar University, Egypt.
Assmaa SelimHistology and Cell Biology Departement, Faculty of Medicine, Zagazig University.
Mohammed AlghamdyMedical Laboratories Department, Faculty of Applied Medical Sciences, Taif University, Saudi Arabia.
Taif University · SAZagazig University · EGAl-Azhar University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMany recent studies support the idea that osteopontin (OPN) can be used to predict the success of pegylated interferon (PEG IFN) alpha-2b/ribavirin therapy in chronic HCV patients.

objectiveOur aim was to investigate the role of plasma OPN and its gene polymorphism at nt - 443 in response to PEG IFN in Saudi patients with chronic HCV.

methodsBlood was collected from 87 patients with chronic hepatitis C before treatment, then patients received PEG IFN α2b plus ribavirin combination therapy. Another 25 healthy subjects, matched for age and sex to patients, were enrolled as controls. Single nucleotide polymorphism (SNP) in OPN at nt - 443 and its blood level were analyzed.

resultsThe frequency of patients who reached sustained virological response (SVR) was increased in patients with T/T at nt - 443 than in those with C/C or C/T. Also the frequency of T allele was increased in responders than in non-responders. However, this increase was not statistically significant. The blood level of OPN was significantly increased in non-responders (Mean±SD=37.21±3.9) in comparison to responders (Mean±SD=33.22±4.1).

conclusionOsteopontin blood level can be considered as a reliable predictor to PEG IFN α2b plus ribavirin therapy in chronic HCV Saudi Patients.

Indexed as

AdolescentAdultBiomarkersCase-Control StudiesFemaleHepatitis C, ChronicHumansInterferon-alphaInterferon alpha-2MaleMiddle AgedOsteopontinPolyethylene GlycolsPolymorphism, Single NucleotideRecombinant ProteinsRNA, ViralBiomarkersInterferon-alphaInterferon alpha-2Osteopontinpeginterferon alfa-2bPolyethylene GlycolsRecombinant ProteinsRNA, ViralHCVOPNPEG IFNRT-PCRSNPSVR

Identifiers

PMID29062331
PMCPMC5637021
OpenAlexW2736236842

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.